Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Part of paid clinical trials in Ann Arbor, Michigan.

Sponsor
Barbara Ann Karmanos Cancer Institute
Study ID
NCT00248482
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cisplatin — DRUG
    Cisplatin 60mg/m2 IV day 1 every 21 days x 4 cycles
  • Gleevec™ — DRUG
    Gleevac 400 mg po BID (800mg/day)- fo patients with objective response or stable disease.
  • irinotecan — DRUG
    Irinotecan: 65 mg/m2 IV days 1, 8 every 21 days x 4 cycles

Study Details

RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as irinotecan and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving imatinib mesylate after irinotecan and cisplatin may keep the tumor from coming back. PURPOSE: This phase II trial is studying how well giving imatinib mesylate after irinotecan and cisplatin works in treating patients with extensive-stage small cell lung cancer.

Key Dates

Start date
Feb 28, 2002
Status verified
Apr 2013
Primary completion
Apr 30, 2005
Completion
Jan 31, 2008

Study Design

Enrollment
6 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Irinotecan, Cisplatin & Gleevec™
    Cisplatin 60mg/m2 IV day 1 every 21 days x 4 cycles Gleevec™ 400 mg po BID (800mg/day)- for patients with objective response or stable disease. Irinotecan 65 mg/m2 IV days 1, 8 every 21 days x 4 cycles

Primary Outcome Measure

Progression-free survival [ Time Frame: at 4 months ]

Locations (2)

FacilityCityStateZIPSite coordinators
University of Michigan Comprehensive Cancer CenterAnn ArborMichigan48109-0942-
Barbara Ann Karmanos Cancer InstituteDetroitMichigan48201-1379-

Find similar trials in Ann Arbor, MI

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
University of Michigan Comprehensive Cancer Center· Ann Arbor, MIBarbara Ann Karmanos Cancer Institute· Detroit, MI

Related Studies